KALV
Price
$12.13
Change
-$0.04 (-0.33%)
Updated
May 3, 6:59 PM EST
60 days until earnings call
RYTM
Price
$43.76
Change
+$2.78 (+6.78%)
Updated
May 3, 6:59 PM EST
One day until earnings call
Ad is loading...

KALV vs RYTM ᐉ Comparison: Which is Better to Invest?

Header iconKALV vs RYTM Comparison
Open Charts KALV vs RYTMBanner chart's image
KalVista Pharmaceuticals
Price$12.13
Change-$0.04 (-0.33%)
Volume$127.16K
CapitalizationN/A
Rhythm Pharmaceuticals
Price$43.76
Change+$2.78 (+6.78%)
Volume$499.06K
CapitalizationN/A
View a ticker or compare two or three
KALV vs RYTM Comparison Chart

Loading...

KALVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RYTMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
KALV vs. RYTM commentary
May 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KALV is a Hold and RYTM is a Hold.

COMPARISON
Comparison
May 06, 2024
Stock price -- (KALV: $12.13 vs. RYTM: $43.76)
Brand notoriety: KALV and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KALV: 38% vs. RYTM: 166%
Market capitalization -- KALV: $511.74M vs. RYTM: $2.67B
KALV [@Biotechnology] is valued at $511.74M. RYTM’s [@Biotechnology] market capitalization is $2.67B. The market cap for tickers in the [@Biotechnology] industry ranges from $545.88B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KALV’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • KALV’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, both KALV and RYTM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KALV’s TA Score shows that 5 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • KALV’s TA Score: 5 bullish, 4 bearish.
  • RYTM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KALV is a better buy in the short-term than RYTM.

Price Growth

KALV (@Biotechnology) experienced а +12.52% price change this week, while RYTM (@Biotechnology) price change was +14.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.98%. For the same industry, the average monthly price growth was -3.07%, and the average quarterly price growth was +64.82%.

Reported Earning Dates

KALV is expected to report earnings on Jul 05, 2024.

RYTM is expected to report earnings on Jul 30, 2024.

Industries' Descriptions

@Biotechnology (+3.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for KALV with price predictions.
OPEN
A.I.dvisor published
a Summary for RYTM with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RYTM($2.67B) has a higher market cap than KALV($512M). KALV YTD gains are higher at: -0.980 vs. RYTM (-4.807).
KALVRYTMKALV / RYTM
Capitalization512M2.67B19%
EBITDAN/AN/A-
Gain YTD-0.980-4.80720%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
KALV vs RYTM: Fundamental Ratings
KALV
RYTM
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10053
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4637
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALV's Valuation (60) in the Pharmaceuticals Other industry is in the same range as RYTM (75) in the Biotechnology industry. This means that KALV’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (53) in the Biotechnology industry is somewhat better than the same rating for KALV (100) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew somewhat faster than KALV’s over the last 12 months.

RYTM's SMR Rating (98) in the Biotechnology industry is in the same range as KALV (98) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew similarly to KALV’s over the last 12 months.

RYTM's Price Growth Rating (37) in the Biotechnology industry is in the same range as KALV (46) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew similarly to KALV’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew similarly to KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KALVRYTM
RSI
ODDS (%)
Bullish Trend 4 days ago
77%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
67%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 6 days ago
81%
View a ticker or compare two or three
Ad is loading...
KALVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RYTMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FUNYX34.530.41
+1.20%
Pioneer Fundamental Growth Y
SLYCX15.210.17
+1.13%
SEI Large Cap Y (SIMT)
TPVIX19.240.13
+0.68%
Timothy Plan Small Cap Value I
VSSLX39.250.23
+0.59%
JPMorgan Small Cap Sustainable Ldrs R6
IPEIX6.180.03
+0.49%
Voya Large Cap Value Port I

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
-0.33%
ATXS - KALV
38%
Loosely correlated
+2.14%
PLRX - KALV
38%
Loosely correlated
+5.51%
VSTM - KALV
37%
Loosely correlated
+5.21%
BCRX - KALV
37%
Loosely correlated
-0.67%
DNLI - KALV
36%
Loosely correlated
+1.96%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with FOLD. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then FOLD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+6.78%
FOLD - RYTM
36%
Loosely correlated
-0.29%
PCVX - RYTM
35%
Loosely correlated
+2.18%
KALV - RYTM
34%
Loosely correlated
-0.33%
DNLI - RYTM
33%
Loosely correlated
+1.96%
KURA - RYTM
33%
Loosely correlated
+0.19%
More